JP2016528180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528180A5 JP2016528180A5 JP2016519629A JP2016519629A JP2016528180A5 JP 2016528180 A5 JP2016528180 A5 JP 2016528180A5 JP 2016519629 A JP2016519629 A JP 2016519629A JP 2016519629 A JP2016519629 A JP 2016519629A JP 2016528180 A5 JP2016528180 A5 JP 2016528180A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- following structure
- chr
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 232
- 125000000623 heterocyclic group Chemical group 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 20
- 238000010276 construction Methods 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- -1 racemates Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims description 4
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000008484 agonism Effects 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 108010063919 Glucagon Receptors Proteins 0.000 claims description 2
- 102100040890 Glucagon receptor Human genes 0.000 claims description 2
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 claims description 2
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 claims description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims description 2
- 206010064720 Lack of satiety Diseases 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 150000004283 biguanides Chemical group 0.000 claims description 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims description 2
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 206010021654 increased appetite Diseases 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 108010004367 lixisenatide Proteins 0.000 claims description 2
- 229960001093 lixisenatide Drugs 0.000 claims description 2
- 229950004994 meglitinide Drugs 0.000 claims description 2
- 230000006371 metabolic abnormality Effects 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 2
- 229960004034 sitagliptin Drugs 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 108010048573 taspoglutide Proteins 0.000 claims description 2
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 2
- 229950007151 taspoglutide Drugs 0.000 claims description 2
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 0 O=C(CCc(cc1)ccc1-c(nc1)ncc1C1=CC=C*C=C1)I Chemical compound O=C(CCc(cc1)ccc1-c(nc1)ncc1C1=CC=C*C=C1)I 0.000 description 11
- 238000000034 method Methods 0.000 description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N NC(c1ccccc1)=O Chemical compound NC(c1ccccc1)=O KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361833737P | 2013-06-11 | 2013-06-11 | |
| US61/833,737 | 2013-06-11 | ||
| US201461981643P | 2014-04-18 | 2014-04-18 | |
| US61/981,643 | 2014-04-18 | ||
| PCT/US2014/041997 WO2014201172A1 (en) | 2013-06-11 | 2014-06-11 | Novel glp-1 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528180A JP2016528180A (ja) | 2016-09-15 |
| JP2016528180A5 true JP2016528180A5 (enExample) | 2017-07-06 |
| JP6573604B2 JP6573604B2 (ja) | 2019-09-11 |
Family
ID=51136825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519629A Expired - Fee Related JP6573604B2 (ja) | 2013-06-11 | 2014-06-11 | 新規なｇｌｐ−１レセプターモジュレーター |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9260427B2 (enExample) |
| EP (1) | EP3008056B8 (enExample) |
| JP (1) | JP6573604B2 (enExample) |
| KR (1) | KR102271179B1 (enExample) |
| CN (2) | CN105593225B (enExample) |
| AU (1) | AU2014278183B2 (enExample) |
| BR (1) | BR112015031040A8 (enExample) |
| CA (1) | CA2913791A1 (enExample) |
| EA (1) | EA030857B1 (enExample) |
| ES (1) | ES2864349T3 (enExample) |
| HK (1) | HK1222176A1 (enExample) |
| MX (1) | MX370666B (enExample) |
| WO (1) | WO2014201172A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| HK1202119A1 (en) | 2011-12-12 | 2015-09-18 | Celgene International Ii Sàrl | Novel glp-1 receptor modulators |
| CN105593225B (zh) | 2013-06-11 | 2019-04-16 | 赛尔基因第二国际有限公司 | 新型glp-1受体调节剂 |
| CN107074820B (zh) * | 2014-07-25 | 2021-05-18 | 赛尔基因第二国际有限公司 | Glp-1受体调节剂 |
| KR102497644B1 (ko) * | 2014-12-10 | 2023-02-08 | 리셉토스 엘엘씨 | Glp-1 수용체 조절제 |
| CN114539273A (zh) | 2016-06-07 | 2022-05-27 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| HRP20241239T1 (hr) | 2017-03-23 | 2024-12-06 | Jacobio Pharmaceuticals Co., Ltd. | Novi heterociklički derivati korisni kao shp2 inhibitori |
| WO2018200833A1 (en) * | 2017-04-28 | 2018-11-01 | Celgene International Ii Sarl | Novel glp-1 receptor modulators |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN109608524B (zh) * | 2018-11-09 | 2022-06-03 | 北京志道生物科技有限公司 | 兼具dpp-4抑制及glp1r激活活性的多肽衍生物、制备和应用 |
| DK4097099T3 (da) | 2020-02-07 | 2024-07-15 | Gasherbrum Bio Inc | Heterocyckliske GLP1-agonister |
| CN111548311B (zh) * | 2020-06-04 | 2021-04-23 | 山西医科大学 | 一种小分子glp-1r激动剂及其应用 |
| CR20230066A (es) | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
| US20250188103A1 (en) | 2022-03-09 | 2025-06-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250206757A1 (en) | 2022-03-21 | 2025-06-26 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| JP2025513071A (ja) | 2022-04-14 | 2025-04-22 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN114989204A (zh) * | 2022-06-16 | 2022-09-02 | 西北工业大学 | 一种葡萄糖响应自修复凝胶用的二苯乙炔类液晶态交联剂的制备方法 |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1062206B (it) | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | Derivati della tirosina attivi sulla muscolatura liscia |
| DE2423536A1 (de) | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| SK94393A3 (en) * | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| JPH09504302A (ja) * | 1993-11-01 | 1997-04-28 | 日本チバガイギー株式会社 | エンドセリン・レセプター・アンタゴニスト |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| DE69831673C5 (de) | 1997-01-07 | 2015-01-22 | Amylin Pharmaceuticals, Llc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| AR016133A1 (es) * | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| JP2001512139A (ja) * | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Ｖｌａ−４が介在する白血球接着を阻害するスルホニル化ジペプチド化合物 |
| DK1005445T3 (da) * | 1997-08-22 | 2004-10-04 | Hoffmann La Roche | N-alkanoylphenylaninderivater |
| JP3727536B2 (ja) * | 1997-08-22 | 2005-12-14 | エフ．ホフマン−ラ ロシュ アーゲー | Ｎ−アルカノイルフェニルアラニン誘導体 |
| US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| JP4245682B2 (ja) * | 1997-12-25 | 2009-03-25 | 協和発酵キリン株式会社 | キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤 |
| US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DK1137666T5 (da) | 1998-12-07 | 2009-10-05 | Univ Tulane | GLP-1-analoger |
| BRPI0007820B8 (pt) | 1999-01-14 | 2021-05-25 | Amylin Pharmaceuticals Llc | formulações farmacêuticas agonistas de exendina e seus usos |
| EP1150565A1 (en) * | 1999-02-08 | 2001-11-07 | LION bioscience AG | Thiazole derivatives and combinatorial libraries thereof |
| JP3795305B2 (ja) * | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| DE60033684T2 (de) * | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | Phenylalaninderivate |
| CN1196682C (zh) * | 1999-12-06 | 2005-04-13 | 霍夫曼-拉罗奇有限公司 | 4－吡啶基－n－酰基－l－苯丙氨酸 |
| WO2001066531A1 (de) | 2000-03-07 | 2001-09-13 | Aventis Pharma Deutschland Gmbh | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase |
| US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| AU7874001A (en) * | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
| AU2001290303A1 (en) * | 2000-09-29 | 2002-04-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| EP1454898A4 (en) * | 2001-12-13 | 2006-12-13 | Ajinomoto Kk | NEW PHENYL ALANIDE DERIVATIVES |
| EP1477482B1 (en) * | 2002-02-20 | 2010-04-14 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
| JPWO2003089410A1 (ja) * | 2002-04-19 | 2005-08-25 | 協和醗酵工業株式会社 | フェニルアラニン誘導体 |
| US20070276034A1 (en) | 2002-05-31 | 2007-11-29 | Luke Esposito | Compounds, compositions and methods for the treatment of synucleinopathies |
| EP1537116B1 (en) | 2002-09-04 | 2010-06-02 | Schering Corporation | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
| EP2194058B1 (en) | 2002-09-04 | 2013-11-27 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
| US20040152750A1 (en) | 2002-12-20 | 2004-08-05 | Kodra Janos Tibor | Novel glucagon antagonists |
| WO2004074264A1 (ja) * | 2003-02-20 | 2004-09-02 | Ajinomoto Co., Inc. | キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体 |
| AU2004247389C1 (en) | 2003-06-13 | 2010-05-27 | Laboratorios S.A.L.V.A.T., S.A. | New benzamides as PPARY modulators |
| EP1700850B1 (en) * | 2003-12-22 | 2015-07-15 | Ajinomoto Co., Inc. | Phenylalanine derivative |
| EP1720839A1 (en) * | 2004-02-10 | 2006-11-15 | Janssen Pharmaceutica N.V. | Pyridazinones as antagonists of a4 integrins |
| JP2005263787A (ja) * | 2004-02-17 | 2005-09-29 | Ishihara Sangyo Kaisha Ltd | アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| WO2006117743A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Substituted aromatic compounds as antidiabetic agents |
| WO2006127595A1 (en) | 2005-05-23 | 2006-11-30 | Arena Pharmaceuticals, Inc. | 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| CN102503899B (zh) * | 2005-06-21 | 2014-09-24 | 味之素株式会社 | 苯基丙氨酸衍生物的结晶、其制备方法及其应用 |
| US20090137601A1 (en) * | 2005-11-23 | 2009-05-28 | Astrazeneca Ab | L-Phenylalanine Derivatives |
| US20080045521A1 (en) * | 2006-06-09 | 2008-02-21 | Astrazeneca Ab | Phenylalanine derivatives |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| JP5273587B2 (ja) * | 2006-11-22 | 2013-08-28 | 味の素株式会社 | キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体 |
| WO2008064823A1 (en) * | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| US8618324B2 (en) | 2007-03-13 | 2013-12-31 | Board Of Regents, The University Of Texas System | Composition and method for making oligo-benzamide compounds |
| WO2008149382A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| EP2205085A1 (en) * | 2007-09-25 | 2010-07-14 | Merck Sharp & Dohme Corp. | 2-aryl or heteroaryl indole derivatives |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| EP2993173A1 (en) * | 2010-03-29 | 2016-03-09 | Ajinomoto Co., Inc. | Crystals of salts of phenylalanine derivatives |
| US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| US8999975B2 (en) * | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| HK1202119A1 (en) * | 2011-12-12 | 2015-09-18 | Celgene International Ii Sàrl | Novel glp-1 receptor modulators |
| CN105593225B (zh) | 2013-06-11 | 2019-04-16 | 赛尔基因第二国际有限公司 | 新型glp-1受体调节剂 |
| CN107074820B (zh) | 2014-07-25 | 2021-05-18 | 赛尔基因第二国际有限公司 | Glp-1受体调节剂 |
-
2014
- 2014-06-11 CN CN201480044849.7A patent/CN105593225B/zh not_active Expired - Fee Related
- 2014-06-11 KR KR1020167000708A patent/KR102271179B1/ko not_active Expired - Fee Related
- 2014-06-11 AU AU2014278183A patent/AU2014278183B2/en not_active Ceased
- 2014-06-11 EA EA201592281A patent/EA030857B1/ru not_active IP Right Cessation
- 2014-06-11 HK HK16110427.4A patent/HK1222176A1/zh unknown
- 2014-06-11 JP JP2016519629A patent/JP6573604B2/ja not_active Expired - Fee Related
- 2014-06-11 CA CA2913791A patent/CA2913791A1/en not_active Abandoned
- 2014-06-11 CN CN201910207853.5A patent/CN109867630A/zh active Pending
- 2014-06-11 ES ES14736554T patent/ES2864349T3/es active Active
- 2014-06-11 BR BR112015031040A patent/BR112015031040A8/pt not_active Application Discontinuation
- 2014-06-11 EP EP14736554.8A patent/EP3008056B8/en active Active
- 2014-06-11 US US14/302,260 patent/US9260427B2/en not_active Expired - Fee Related
- 2014-06-11 WO PCT/US2014/041997 patent/WO2014201172A1/en not_active Ceased
- 2014-06-11 MX MX2015016831A patent/MX370666B/es active IP Right Grant
-
2015
- 2015-12-03 US US14/958,513 patent/US9598430B2/en active Active
-
2017
- 2017-01-26 US US15/416,758 patent/US10259823B2/en active Active